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Objective: To analyze the protective efﬁcacy of recombinant 78 kDa antigen of Leish-
mania donovani in combination with two adjuvants, that is, cationic liposomes or MPL-A
against visceral leishmaniasis in BALB/c mice.
Methods: The genomic DNA of promastigotes was isolated and 583 bp of T cell epi-
topes of gene encoding 78 kDa was ampliﬁed using speciﬁc primers. The ampliﬁed gene
was cloned into pET28c, transformed into Escherichia coli BL21 (DE3) and got
expressed after IPTG induction. The recombinant protein was then puriﬁed using Ni-
NTA and named r78. Three groups of mice were immunized with 10 mg of r78 plus
MPL-A, r78 encapsulated in positively charged liposomes and control animals immu-
nized with PBS. Two booster doses were given with the respective vaccine at an interval
of 2 weeks each. Mice were challenged with 1 × 107 Leishmania promastigotes and
sacriﬁced on different post infection/challenge days.
Results: Immunization with r78 along with MPL-A and liposome-encapsulated r78
brought a signiﬁcant reduction in parasite load. In comparison to the infected controls, the
parasite load declined by 96.2% in mice immunized with r78 plus MPL-A and 97.23% in
animals immunized with liposome-encapsulated r78. The immunized animals also
exhibited profound DTH response. The serum antibody responses increased from 15 to
90 days post infection/challenge. Immunized animals showed greater IgG2a levels and
lesser IgG1 levels in comparison to the infected controls. The splenocytes from immu-
nized mice were cultured, stimulated with r78 and analyzed for cytokine proﬁle. The
levels of IL-2 and IFN-g were greater in immunized animals as compared to control mice.
Conclusions: The study proves that r78 in combination with suitable adjuvants is a
potential vaccine candidate and may be instrumental in control of visceral leishmaniasis.1. Introduction
The leishmaniases are responsible for the second-highest
number of deaths due to parasitic infection globally [1]. They
have an overwhelming estimated prevalence of 12 million
infected humans, and cause a burden estimated at 2 357 000
disability-adjusted life years [2]. Leishmaniasis has been
classiﬁed as one of the most neglected diseases, and theestimated disease burden places it second in mortality and
fourth in morbidity among the tropical infections [3]. There is
no satisfactory chemotherapy for cutaneous leishmaniasis.
Existing chemotherapy for visceral leishmaniasis (VL) is, in
general, efﬁcient in immunocompetent patients, but is costly
and not exempt from side-effects [4]. Resistant strains of
Leishmania spp. are emerging, mostly in India [5]. In
immunocompromised patients, relapses after therapy are very
frequent [6]. To date, several approaches to anti-leishmanial
vaccine have been tested. First generation vaccines composed
of whole killed parasites have been proposed. However, most of
the vaccine studies concentrate on the second generation vac-
cines consisting of recombinant proteins, poly-proteins or den-
dritic cells loaded with peptides derived from leishmanial
antigens [1]. For the past 20 years, DNA cloning and
characterization of genes encoding parasite proteins suitable
for the development of deﬁned vaccines have been carried outopen access article under the CC BY-NC-ND
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models, have shown different degrees of protection [1,8–11].
Recombinant Ldccys1 protein elicits protective immune
responses in Leishmania chagasi infected BALB/c mice [12].
BALB/c mice vaccinated with Leishmania major (L. major)
Ribosomal Proteins Extracts combined with CpG
oligodeoxynucleotides have been reported to become resistant
to disease caused by a secondary parasite challenge [13].
Recent studies have shown that subcutaneous vaccination with
liposomal rGP63 partially protected susceptible BALB/c mice
when challenged with L. major promastigotes [14].
2. Materials and methods
2.1. Parasite
Promastigotes of Leishmania donovani (L. donovani), strain
MHOM/IN/80/Dd8 were grown at ambient temperature of
(22 ± 1) C in RPMI-1640 medium supplemented with 10%
FCS. The L. donovani strain was maintained by serial sub-
cultures in the same medium after every 48–72 h [15].
2.2. Animals
Inbred BALB/c mice of either gender, weighing 20–25 g,
were obtained from the Central Animal House of Panjab Uni-
versity, Chandigarh. They were fed with water and mouse feed
ad libitum. The ethical clearance to conduct the experiments was
obtained from Institutional Animal Ethics Committee, Panjab
University, Chandigarh.
2.3. Preparation of recombinant vaccine
2.3.1. Isolation of genomic DNA
Approximately 2 × 108 log phase promastigotes were har-
vested by centrifugation at 4 000 rpm for 15 min at 4 C. The
pellet was washed once with PBS (pH-7.2) and ﬁnally sus-
pended in the same. Parasite DNA was extracted with the help ofFigure 1. Agarose gel analysis of pET28c(+) vector containing 583 bp insert.
Lane 1, 8 = 583 bp fragment of gene encoding 78 kDa; Lane 2, 4, 5, 7 = pETgenomic DNA extraction kit as per manufacturer's protocol
(Zymo Research, USA). The isolated DNA was quantitated by
Nanodrop™.
2.3.2. Designing of primers and PCR ampliﬁcation of
gene fragment encoding 78 kDa
The T cell epitopes of gene encoding 78 kDa were identiﬁed
using ‘MHC Pred’ online software. The region containing
maximum number of T cell epitopes (583 bp) were selected for
ampliﬁcation (Figure 1). The following primers were designed
for ampliﬁcation of 583 bp sequence using IDT ‘Scitools’.
Forward primer −50 GCCATATGGGTGCAACAGC-
TCATCAAGGACT 30
Reverse primer -50 GATGGATCCGTTCTTCGCTTCGA-
CACGTT 30
The restriction enzymes Nde| and BamH1 were included in
the forward and reverse primer sequences respectively for
cloning purpose [in pET-28c(+) vector]. PCR was carried out
using commercially available kits (Chromous Biotech).
Following conditions were used for the ampliﬁcation of coding
region of 583 bp of 78 kDa gene of L. donovani. Initial dena-
turation was performed at 94 C for 10 min and then for 1 min.
Annealing was carried out at 59 C for one minute. Extension
was carried out at 72 C for 1 min and ﬁnal extension was done
at same temperature for ten minutes. PCR was carried out for
thirty ﬁve cycles.
2.3.3. Electrophoresis of DNA in agarose gel
Agarose (0.8%, w/v for genomic DNA and 1%, w/v for PCR
product and plasmid) was dissolved in 1 × TBE buffer by
heating, when it cooled to 50 C, ethidium bromide (0.5 mg/mL)
was added and the gels were cast in the DNA electrophoresis
chamber. After solidiﬁcation of the agarose, DNA samples
containing loading dye buffer (1×) were loaded on to the agarose
gel and run in TBE (1 ×, pH 8.0) buffer. Initially, the gels were
run at a constant voltage of 50 V till the dye front left the wells.
The voltage was then increased to 100 V. A 2 log ladder (NEB,
England) was used as standard DNA marker. The gels were28c vector with 583 bp insert; Lane 3, 6 = pET28c vector without insert.
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(Alpha Imager, India).
2.3.4. Extraction of DNA from preparatory gel
The PCR product was eluted from preparative agarose gel
using gel extraction kit (Geneaid, Taiwan). The eluted DNA was
then run on 1% agarose gel.
2.3.5. Enzymatic digestion and ligation of the vector and
PCR products
Restriction digestions of PCR product and plasmid DNA [pET-
28c(+)] were performed as per the manufacturer's instructions
(MBI Fermentas, Germany). The reaction mixture was mixed
gently and incubated at 37 C. The reaction mixtures were mixed
gently and incubated at 37 C for 15 h. The double digested
plasmid DNA and PCR products were electrophoresed and puri-
ﬁed from the rest of the reaction mixtures with Gel Extraction kit
(Geneaid, Taiwan). Ligation reactions were set up using the line-
arized pET28c and double digested PCR products. The ligation
mixture was incubated at 16 C for 16 h in ligation water bath.
2.3.6. Transformation of recombinant plasmids into
Escherichia coli (E. coli)
The competent E. coli cells were prepared using CaCl2 as
described by Sambrook and Russell [16]. A loopful of E. coliBL21
(DE3) cells from LB agar plate were inoculated into 10mLLB and
incubated overnight at 37 C with shaking at 180 rpm. From the
overnight cultures, 1% inoculum was transferred to fresh LB
broth (100 mL) and incubated at 37 C with shaking (180 rpm)
till OD600 of 0.5 was achieved. The cells were incubated at 4 C
for 20 min and harvested by centrifugation at 1 500 × g for
15 min at 4 C in a precooled rotor. The supernatant was
discarded aseptically and 10 mL of autoclaved and ice cold
CaCl2 (100 mM) solution was added to the cell pellets. The cells
were resuspended by gentle shaking until a homogenous
suspension was achieved. The cell suspension was then kept in
ice for 30 min and again centrifuged (1 500 × g/15 min/4 C).
The supernatant was discarded aseptically and 2 mL of
autoclaved CaCl2 (100 mM) was added to the pellet and again
resuspended gently. The cells were kept on ice overnight prior to
their use. The cells were dispensed into aliquots of 200 mL each.
Glycerol stocks (15%) of these cells were prepared and stored
at −70 C for subsequent use.
Transformation efﬁciency of the competent cells was checked
by transforming them with an uncut plasmid and calculating the
cfu/mg of DNA. The transformation efﬁciency of 1 × 108 cfu/mg
DNA and above were taken as a good competent cell preparation.
Transformation of E. coli BL21 (DE3) cells was carried out as per
the instructions given by Sambrook and Russell [16].
2.3.7. Induction of recombinant 78 kDa (T cell epitope
region) expression
Overnight log phase culture (1%) was transferred to
LB + Km50 and allowed to grow to OD600 of 0.5–0.6 at 37 C,
180 rpm before the expression of (His)6 tagged region was
induced by the addition of IPTG (ﬁnal concentration of 0.1–
1 mM) and incubated at temperatures ranging between 15 C
and 37 C for 3–20 h. The induction was then analyzed by SDS-
PAGE. The gels were stained for 4 h by standard coomassie
brilliant blue R 250 and destained with a methanol (25%)/acetic
acid (10%) solution.2.3.8. Puriﬁcation of recombinant 78 kDa (T cell
epitope region) protein using Ni-NTA
For puriﬁcation of the protein, IPTG induced cells from a
200 mL culture were pelleted, resuspended in lysis buffer (Tris-
Cl 50 mM, pH 7.0, NaCl 300 mM, phenylmethylsulfonyl ﬂuorid
1 mM, lysozyme 1 mM and imidazole 10 mM) and sonicated (at
20 kHz, 30 cycles of 10 s shock followed by 10 s of rest). After
sonication, the cellular debris was removed by centrifugation at
14 000 × g for 15 min at 4 C. The crude cell extract was loaded
onto slurry of nickel-chelating agarose beads 50% (w/v) (2 mL)
also equilibrated with the same buffer. The ﬂow through was
collected and the column was given washings with 5 column
volumes of lysis buffer having imidazole (20 and 30 mM,
respectively). Puriﬁed recombinant protein was then eluted with
lysis buffer amended with imidazole (200 mM). 1 mL fractions
were collected and checked for puriﬁed protein on 10% SDS-
PAGE. The fractions showing puriﬁed protein were then
pooled and dialyzed against Tris-Cl (20 mM, pH 7.0) to remove
imidazole and NaCl. The puriﬁed recombinant protein was then
named r78 (Figure 2).
2.4. In vivo immunization and challenge infection
BALB/c mice were immunized with 10 mg of puriﬁed protein
r78 (region coding for T cell epitope only) along with two ad-
juvants namely monophosphoryl lipid A (MPL-A) (40 mg) and
encapsulation in positively charged liposomes. Two booster
doses with respective vaccine were given at an interval of 2
weeks each. The control animals were injected with PBS only.
15 days after the last immunization, immunized and control
animals were challenged intracardially with 1 × 107 promasti-
gotes of L. donovani.
2.5. Evaluation of infection
The animals were sacriﬁced on 15, 30, 45, 60, 75 and 90 days
post infection/challenge and the course of infection was monitored
by the microscopic examination of Giemsa-stained impression
smears of liver. The parasite load was assessed in terms of Leish-
man Donovan Units by the method of Bradley and Kirkley [17].
2.6. Delayed type hypersensitivity (DTH)
All groups of mice were challenged in the right foot pad with a
subcutaneous injection of leishmanin. Left foot pad was inocu-
lated with PBS. After 48 h, the thickness of right and left foot pad
was measured using a pair of Vernier calipers. Results were
expressed as mean ± SD of percentage increase in the thickness of
the right foot-pad as compared to the left footpad of mice [18].
2.7. ELISA
The speciﬁc serum immunoglobulin G (IgG) isotype anti-
body response was measured by conventional ELISA using
commercially available kits (Bangalore Genei, India). 96-well
ELISA plates were coated with crude antigen. Serum samples
were added at twofold serial dilutions, followed by washes and
addition of isotype speciﬁc HRP-conjugated secondary anti-
bodies (rabbit anti-mouse IgG1 or IgG2a) after which the sub-
strate and chromogen were added and absorbance was read on
an ELISA plate reader at 450 nm [18].
Figure 2. Puriﬁcation of recombinant 78 kDa (T cell epitope region) protein using Ni-NTA.
A Lane1: Pellet of IPTG induced sonicated cells; Lane 2: Whole cell lysate of uninduced cells; Lane 3: Ni-NTA column ﬂowthrough; Lane 4: Whole cell
lysate of IPTG induced cells; Lane 5: Puriﬁed recombinant protein. B Lane 3: Standard protein molecule weight markers; Lane 1, 2, 4, 6, 9, 10: Whole cell
lysate of IPTG induced cells (at different temperatures); Lane 5, 7: Whole cell lysate of uninduced cells; Lane 8: Puriﬁed recombinant protein.
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The lymphocyte culture was obtained from spleens of
immunized BALB/c mice. The cells were isolated and counted,
and, after evaluation of their viability by trypan blue exclusion,
1 × 106 cells per well were cultured in RPMI-1640 containing
20 mM NaHCO3, 10 mM HEPES, 100 U of penicillin per mL,
100 mg of streptomycin per mL, 2 mM L-glutamine, and 10%
fetal calf serum (complete medium), with 50 mL b-mercaptoe-
thanol. The spleen cells were cultured in triplicate in a ﬁnal
volume of 200 mL/well and stimulated with r78 antigen. The
culture was incubated for 72 h at 37 C in a humiﬁed chamber
containing 5% CO2. The IL-4, IL-10, IFN-g and IL-2 levels in
the supernatants were determined by sandwich ELISA, accord-
ing to manufacturer's instructions (Diaclone, France), after
sacriﬁcing all the groups of animals [19].
2.9. Statistical analysis
All the experiments were carried out three times indepen-
dently. All data comparisons were tested for signiﬁcance by
using Student's t-test; P-values below 0.05 were considered
signiﬁcant. Results were expressed as mean ± SD of one of three
independent experiments.
3. Results
3.1. Parasite load
Immunization with r78 along with MPL-A (Sigma, USA)
and liposome-encapsulated r78 brought a signiﬁcant reduction inparasite load when compared with infected controls. In com-
parison to the infected controls, the parasite load declined from
47.0% to 96.2% in case of mice immunized with r78 plus MPL-
A while the reduction was 49.00%–97.23% in animals immu-
nized with liposome-encapsulated r78 (Figure 3A).
3.2. Delayed type hypersensitivity response
The animals immunized with r78 along with adjuvants
exhibited profound DTH response. Signiﬁcant increase in
footpad thickness was observed in immunized mice as compared
to control mice (Figure 3B).
3.3. Anti-leishmanial antibody response
The antibody responses increased from 15 to 90 days post
infection/challenge. Immunized animals showed greater IgG2a
levels and lesser IgG1 levels in comparison to the infected
controls (Figure 4).
3.4. Vaccine-induced cytokine production
The splenic lymphocytes from immunized mice were
cultured, stimulated with r78 and analyzed for the cytokine
proﬁle. The levels of IL-2, IFN- g, IL-4 and IL-10 secreted by
cells were measured by using cytokine assay kit according to the
manufacturer's instructions (Diaclone, France). The levels of
IFN- g and IL-2 were greater in immunized animals as
compared to control mice. However the concentration of IL-4
and IL-10 was lesser in immunized animals as compared to
the control mice (Figures 5 and 6).
Figure 4. IgG1 levels and IgG2a levels in mice immunized with r78 plus
different adjuvants.
A: IgG1 levels; B: IgG2a levels. Control vs. r78 + MPL-A/Liposome-
encapsulated r78,*P < 0.05.
Figure 5. IFN-g and IL-2 levels in mice immunized with r78 plus different
adjuvants.
A: IFN-g level; B: IL-2 level. Control vs. r78 + MPL-A/Liposome-
encapsulated r78, *P < 0.05.
Figure 3. Leishman-Donovan units and percentage increase in footpad
thickness (DTH response) of mice immunized with r78 plus different ad-
juvants.
A: Leishman-Donovan units; B: Percentage increase in footpad thickness.
Control vs. r78 + MPL-A/Liposome-encapsulated r78, *P < 0.05.
Figure 6. IL-4 and IL-10 levels in mice immunized with r78 plus different
adjuvants.
A: IL-4 level; B: IL-10 level. Control vs. r78 + MPL-A/Liposome-encap-
sulated r78, *P < 0.05.
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The treatment options for leishmaniasis are limited and the
increased resistance to ﬁrst line drugs and toxicity of second line
drugs makes the development of effective vaccine against the
disease highly desirable. Though we say, on the basis of present
available data, that there is no effective vaccine against any form
of human leishmaniasis, yet, the palpable immunity in a person
against reinfection following recovery from the disease strongly
gives inkling of the feasibility of vaccination against leishman-
iasis [20]. Previously, in our laboratory, we worked on the
protective efﬁcacy of 78 kDa antigen of L. donovani against
murine visceral leishmaniasis [19]. The antigen was found to
be effective against the disease though the protection afforded
was not complete. Therefore, in the current study we worked
on the recombinant version of the antigen in combination with
two different adjuvants: MPL-A and cationic liposomes. The
efﬁcacy of the vaccine was tested in terms of parasite burden and
generation of immune responses.
BALB/c mice immunized with r78 alone and in combination
with MPL-A or cationic liposomes showed a signiﬁcant reduc-
tion in parasite load as compared to the infected controls. Least
parasite burden was observed in mice immunized with
liposome-encapsulated r78. Our results are in consistence with
previous studies which showed the efﬁcacy of recombinant
proteins against leishmaniasis. Animals immunized with the
recombinant protein presented approximately a 100-fold reduc-
tion in parasite burden compared to controls that received PBS,
BCG or Propionibacterium acnes alone [6]. In contrast to our
study where immunization with liposome-encapsulated r78
was slightly more effective in reducing the parasite burden as
compared to r78 given along with MPL-A, vaccination with
liposomal rGP63 along with MPL-TDM showed almost 2-
logfold, and 7–10-log-fold reduction in parasite burden
compared to mice boosted with liposomal rGP63 and unvacci-
nated mice, respectively [21]. However, immunization with
recombinant isolates of LeIF, LmSTI1 and TSA from
Leishmania braziliensis (L. braziliensis) individually or in
combination did not protect mice against challenge infection
with L. braziliensis despite the induction of antibody and cell
mediated responses [22].
The humoral responses to the vaccines were characterized by
analyzing the distribution of IgG, IgG1 and IgG2a speciﬁc an-
tibodies in the serum samples of immunized and control animals.
ELISA results showed that immunized groups developed higher
level of antibody responses than control animals. The IgG1
response is an indicator of Th2 type of immune response and
IgG2a antibody response corresponds to Th1 response which is
protective. The immunized animals revealed lesser IgG1 and
higher IgG2a responses as compared to the infected controls.
Among the immunized groups, the serum antibody levels in
mice immunized with liposome-encapsulated r78 and r78 along
with MPL-A were comparable.
A typical DTH reaction is characterized by activation and
recruitment predominantly of T cells and macrophages at the site
of intradermal injection in previously sensitized host. Peak DTH
responses were observed in animals which were immunized with
liposome-encapsulated r78 vaccine and these were followed by
animals immunized with r78+MPL-A. The immunized mice
developed a strong cell-mediated immune response and thereby
resisted the challenge by parasites. The results demonstrated apositive correlation between enhanced DTH response and
reduced parasite load for all groups.
The immune response (Th1 or Th2) generated by various
vaccine formulations was assessed by quantifying the cytokines
(IFN-g, IL-2, IL-4 and IL-10) produced by splenocytes of
vaccinated animals. Immunized animals showed greater IFN- g
and IL-2 levels as compared to the control group. Also, the
levels of IL-4 and IL-10 were greater in control animals as
compared to the immunized animals. High levels of IFN-g
indicate the development of a protective Th1 immune response.
This IFN-g is found to come from natural killer cells and is
thought to play an important role as a component of innate
immune mechanism for the activation of macrophages. Similar
to our study, rLdccys1 induced a signiﬁcant secretion of IFN-g
and nitric oxide (NO) [6]. Immunization of mice with
recombinant LeIF stimulates the induction of Th1 type
immune response with increased production of IFN-g [23],
Similarly, signiﬁcantly higher levels of IFN-g and IL-12 were
observed in groups of mice receiving rGP63 in presence of li-
posomes and MPL-TDM during prime and boost than mice
receiving liposomal rGP63 during boost, after L. donovani
challenge infection [21]. While MPL is reported to promote IFN-
g production by Ag-speciﬁc CD4+ T cells and skewing the
immune response towards Th1 type [24], liposomal Ag showed
protective response against leishmaniasis [25]. IL-2 plays a crit-
ical role in priming naive CD4+ T cells to become IL-4 or IFN- g
producers [26] and it is a principal T cell growth factor for Th1
type of immune response. IL-10 represents the main
macrophage-deactivating cytokine and plays an important reg-
ulatory role in the progression of VL [27].Our results are in
consistence with those obtained from murine leishmaniasis
model of both cutaneous and visceral diseases where
expression of IFN-g is associated with control of infection
[28,29]. Our results are also in correspondence with the studies
which showed that mice immunized with 78 kDa
antigen + MPL-A signiﬁcantly brought down the IL-4 and IL-
10 levels in immunized mice [19]. Studies have also shown
that immunization with Leish-111f + MPL-SE protected mice
and hamsters against L. infantum infection that correlated with
induction of Th1 immune response as characterized with
production of IFN-g, TNF and IL-2 with little IL-4 [30]. High
levels of IL-10 in infected control animals supported the view
that upregulation of this cytokine is accompanied by disease
progression and depressed Th1 type of cell mediated immunity
with decreased production of IFN-g and IL-12 [31,32]. Previous
studies have also conﬁrmed that IL-10 suppresses Th1
response, which plays a protective role against active VL [33].
Moreover studies have shown that IL-10 gene deﬁcient mice
are resistant to L. donovani infection and produce more IFN- g
and IL-12 [34].
In light of these observations, the present study suggests that
a recombinant vaccine based on r78 given along with liposomes
and MPL-A as adjuvants is protective against experimental
murine visceral leishmaniasis and can be further tested in higher
animal models to establish its potential as a vaccine candidate
against the disease.
The study proves that r78 in combination with suitable ad-
juvants is a potential vaccine candidate and may be instrumental
in control of visceral leishmaniasis. Further studies are required
to explore these vaccines in higher animal models and establish
their prophylactic potential.
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